Affordable Access

deepdyve-link
Publisher Website

[Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotype 1 and 4 patients with slow virologic response].

Authors
  • Kim, In Hee1
  • 1 Department of Internal Medicine, The Research Institute for Medical Science, Chonbuk National University Medical School, Jeonju, Korea. [email protected] , (North Korea)
Type
Published Article
Journal
The Korean journal of hepatology
Publication Date
Jun 01, 2010
Volume
16
Issue
2
Pages
201–205
Identifiers
DOI: 10.3350/kjhep.2010.16.2.201
PMID: 20606507
Source
Medline
License
Unknown

Abstract

Extending therapy with peginterferon alfa-2a/ribavirin to 72 weeks decreases the probability of relapse in patients with an EVR. If they can be maintained on extended-duration therapy, SVR rates also may improve.

Report this publication

Statistics

Seen <100 times